In addition, we are eligible to receive tiered royalties on net sales of ALPN-101. ICOS is, however, rapidly induced upon T cell activation. We plan to determine expansion cohorts later this year. More information is available at www.clinicaltrials.gov (NCT04186637). Examples of additional multi-target compounds for immuno-oncology are highlighted below. Each of these patent applications is solely owned by us. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty. A company can make only those claims relating to safety and efficacy approved by the FDA. Such off-label uses are common across medical specialties. These laws may impact, among other things, our proposed sales and marketing strategies. Moreover, clinical data are often susceptible to varying interpretations and analyses. In most countries, the pricing of prescription drugs is subject to governmental control. We have had significant operating losses since inception. Our business may be affected by litigation and government investigations. However, we may never receive such designation. Therefore, these provisions could adversely affect the price of our stock. Item 1B. Unresolved Staff Comments.